# Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

> **NCT02828111** · PHASE2 · COMPLETED · sponsor: **PellePharm, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Basal Cell Carcinomas

## Interventions

- **DRUG:** Patidegib
- **DRUG:** Vehicle gel

## Key facts

- **NCT ID:** NCT02828111
- **Lead sponsor:** PellePharm, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-11
- **Primary completion:** 2017-11-09
- **Final completion:** 2017-11-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02828111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02828111, "Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02828111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*